Document is current
Any future updates will be listed below
-
Authors
Shephard, Adam J. https://orcid.org/0000-0003-0969-2990
Mahmood, Hanya https://orcid.org/0000-0001-7159-0368
Raza, Shan E. Ahmed https://orcid.org/0000-0002-1097-1738
Khurram, Syed Ali
Rajpoot, Nasir M. https://orcid.org/0000-0002-4706-1308
-
Funding
Funding for this research was provided by:
Cancer Research UK (C63489/A29674, C63489/A29674, C63489/A29674)
DH | National Institute for Health Research (NIHR300904)
- License Information
-
More Information
Article History
Received: 22 August 2024
Revised: 11 November 2024
Accepted: 19 November 2024
First Online: 30 November 2024
Competing interests
: NMR is the co-founder, CEO and CSO of Histofy Ltd., UK. He is also the GSK Chair of Computational Pathology and is in receipt of research funding from GSK and AstraZeneca. SAK is a shareholder of Histofy Ltd. All other authors have no competing interests to declare.
: Ethical approval was obtained by the NHS Health Research Authority West Midlands (18/WM/0335) and experiments were conducted in compliance with the Declaration of Helsinki. Written consent was not required as data was collected from surplus archived tissue. Data collected were fully anonymised.
